SCHEMBL6324209

SCHEMBL6324209

COc1ccc(-c2noc(N)c2C(=O)NCc2ccc3c(c2)OCO3)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 2/20 0.58
GAA P10253 1/20 0.57
PKM P14618 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HPGD P15428 1/20 0.48
TP53 P04637 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
FAAH O00519 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH2 P05091 1/20 0.46
HCRTR1 O43613 1/20 0.46
HCRTR2 O43614 1/20 0.46
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321897 0.85 SMN1; SMN2 (0.47) RECQLSMN1; SMN2ALDH1A1PKMHPGD
SCHEMBL6323629 0.85 MET (0.44) RECQLSMN1; SMN2ALDH1A1RAB9AROCK2
SCHEMBL6316520 0.84 MAPT (0.52) ALDH1A1NPC1RAB9AHPGDTP53
SCHEMBL6323365 0.84 CDK2 (0.47) SMN1; SMN2ALDH1A1RAB9ATP53MEN1
SCHEMBL6324039 0.83 ALDH1A1 (0.52) ALDH1A1GAARAB9AHPGDMEN1
SCHEMBL6323609 0.83 ADORA2A (0.48) ALDH1A1HPGDTP53ROCK2ROCK1
SCHEMBL6316080 0.83 ALDH1A1 (0.48) RECQLSMN1; SMN2ALDH1A1GAAHPGD
SCHEMBL6315498 0.82 POLB (0.52) ALDH1A1NPC1HPGDHCRTR1HCRTR2
SCHEMBL6316258 0.82 GAA (0.63) RECQLSMN1; SMN2ALDH1A1GAAPKM
SCHEMBL6315541 0.81 GSK3B (0.46) SMN1; SMN2ALDH1A1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RECQL 2512/4885SMN1; SMN2 2766/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.